Kin Meds: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://kinmeds.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.

1. 1

   ““Same Active Ingredient as common brands””

2. 2

   ““Hit weight management goals with the same weight loss ingredient as brand-name GLP-1 medications, at a fraction of the cost””

3. 3

   “The compounded semaglutide and tirzepatide products displayed on your website identify “Kin Meds” on the pictured label, suggesting Kin Meds is the compounder of those drugs when in fact it is not.”

4. 4

   “Compounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.”

1. 1

   Letter issued

   February 2026

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

kinmeds.com returned a live storefront when we checked in August 2026, listing branded and personalised GLP-1 options alongside hormone, men's health, skin and sexual-health products and lab biomarkers. We did not review every page on the site.

This is the sentence a pricing site exists to examine, because it does two jobs at once. "The same weight loss ingredient as brand-name GLP-1 medications" establishes equivalence; "at a fraction of the cost" collects the payoff. Remove the first clause and the second is just a low price, which is fine and needs no defending. Keep them together and the low price reads as a pure saving with nothing given up — and that is the inference FDA objected to, because the compounded product has not been through the review the brand-name product has. The letter says nothing about whether the price is fair, whether the medication works, or how the company operates. What it usefully establishes is that "a fraction of the cost" is a comparison between two different kinds of product, so the gap is not all margin. Some of it is the review that one of them has and the other does not.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Kin Meds failed to respond.